What is INDOSE?
INDOSE operates as a pioneering force in the vaporizer industry, distinguished by its development of the world's first real-time, metered precise dosage device. Co-founded by industry veterans including Benzi Ronen, the company leverages extensive experience in product lifecycle management and retail distribution to address the critical need for consistency and safety in inhalation-based delivery. By integrating sophisticated hardware engineering with user-centric design, INDOSE effectively mitigates the variability traditionally associated with consumption, positioning itself as a high-authority player in the evolving wellness and pharmaceutical-adjacent technology landscape.
How much funding has INDOSE raised?
INDOSE has raised a total of $3.6M across 2 funding rounds:
Series A
$3.5M
Debt
$145K
Series A (2019): $3.5M with participation from Casa Verde Capital
Debt (2021): $145K led by PPP
Key Investors in INDOSE
Casa Verde Capital
Casa Verde is a premier venture capital firm dedicated exclusively to the cannabis sector, prioritizing scalable and capital-efficient enterprises led by elite management teams.
PPP
Public-Private Partnership
What's next for INDOSE?
With the successful acquisition of $145K, INDOSE is strategically positioned to accelerate its enterprise-level expansion. The current lifecycle stage suggests a transition from initial product validation to broad-scale market adoption. Future initiatives will likely focus on deepening retail partnerships, enhancing supply chain resilience, and potentially expanding the product portfolio to address diverse therapeutic applications. As the regulatory environment matures, the company's emphasis on precision and data-backed delivery will serve as a significant competitive moat, allowing it to capture additional market share while maintaining its reputation for technological excellence and consumer safety.
See full INDOSE company page
